Comparative Efficacy of High- and Low-Dose Ceftriaxone Regimens: A Systematic Review and Meta-Analysis
Annals of Pharmacotherapy · 2025
DOI: 10.1177/10600280251346777 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Lindsay Brust-Sisti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA. Hauptthemen laut MEDLINE: Ceftriaxone, Anti-Bacterial Agents. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Objective
To compare the efficacy and safety of ceftriaxone (CRO) 1 g intravenously (IV) daily to higher doses for treating non-central nervous system (CNS) infections in adults. Data Sources: PubMed, Embase, Scopus, and Web of Science were used. A search was run from database inception to August 8, 2023 and rerun May 12, 2025. Search terms were CRO, Rocephin, pneumonia, intra-abdominal infections, appendicitis, typhlitis, pyelonephritis, bacteremia, and sepsis. Study Selection and Data Extraction: Articles included had to compare CRO 1 g IV daily to higher dosing for the outcomes of interest: clinical cure (CC), hospital length of stay (LOS), mortality, and toxicity. Randomized controlled trials (RCTs) or observational studies were included. Studies including pediatric, pregnant, and outpatient administration were excluded. Clinical cure was evaluated using a Mantel-Haenszel random-effects model with Peto odds ratios (pORs), and 95% confidence intervals (CIs) were calculated. Heterogeneity was identified using Cochrane I 2 statistic. Data Synthesis: Eight studies (5145 patients) were included. No statistically significant difference was found for CC (pOR 0.958; 95% CI [0.525-1.749]; I 2 = 60.23; P = .888); LOS (Std difference in means, 0.052; 95% CI [−0.418, 0.523]; I 2 = 96.047; P = .828); or mortality (pOR 0.932; 95% CI [0.789-1.100]; I 2 = 0.000; P = .405). Relevance to Patient Care and Clinical Practice: Ceftriaxone dosing ranges from 1 to 2 g IV daily for treating non-CNS infections. Optimal dosing remains controversial, as RCTs have used different doses. This meta-analysis showed no difference between high and low CRO dosing for efficacy and safety. Because infection type and pharmacokinetic factors were not accounted for, findings may not be applicable to certain high-risk infections or situations where CRO pharmacokinetics are altered, such as hypoalbuminemia. Prospective studies can compare regimens and confirm findings.
Conclusions
Ceftriaxone doses greater than 1 g IV daily did not improve CC, LOS, or mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
- Jersey City Medical Center, Jersey City, NJ, USA.
- Robert Wood Johnson University Hospital Somerset, Somerville, NJ, USA.
- Robert Wood Johnson Library of the Health Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
- Jersey Shore University Medical Center, Neptune, NJ, USA.
ORCID-Profile: Lindsay Brust-Sisti, Luigi Brunetti, Jimmy Gonzalez
Zitieren
APA
Brust-Sisti, L., Hu, G. Y., Bridgeman, M., Brunetti, L., & Gonzalez, J. (2025). Comparative Efficacy of High- and Low-Dose Ceftriaxone Regimens: A Systematic Review and Meta-Analysis. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251346777
Vancouver
Brust-Sisti L, Hu GY, Bridgeman M, Brunetti L, Gonzalez J. Comparative Efficacy of High- and Low-Dose Ceftriaxone Regimens: A Systematic Review and Meta-Analysis. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280251346777
BibTeX
@article{BrustSisti2025,
author = {Brust-Sisti, Lindsay and Hu, Gwang-Yee and Bridgeman, Matthew and Brunetti, Luigi and Gonzalez, Jimmy},
title = {Comparative Efficacy of High- and Low-Dose Ceftriaxone Regimens: A Systematic Review and Meta-Analysis},
journal = {Annals of Pharmacotherapy},
year = {2025},
doi = {10.1177/10600280251346777}
}
EUVIMED